Pramlintide Research

Secher A, Lutz TA, Raun K

Amylin is a glucoregulatory peptide hormone discovered in 1986. Almost 20 years later, pramlintide, a human amylin analogue, emerged as the first amylin-based drug, approved as an adjunct treatment to insulin for type 1 diabetes (T1D) and type 2 diabetes (T2D). Despite its effects on multiple org...

Alhalabi H, Borschel L, Le Foll C, Thomas A, Bally L, Thevis M et al.

Peptide hormone-based weight-loss therapeutics have gained increasing attention, driven amongst other reasons, by the clinical and commercial success of semaglutide. Their increasing accessibility raises concerns about their potential misuse in sports, especially in disciplines where weight manag...

Nordell P, Jansson-Löfmark R, Gennemark P

Peptide-based therapeutics represent a rapidly expanding class of drugs. Endogenous peptides typically exhibit short elimination half-lives due to proteolytic cleavage and renal filtration. However, modifications such as amino acid substitutions and fatty-acid conjugation can significantly prolon...

Chung CW, Kim J

Amylin is a pancreatic peptide hormone that regulates blood glucose levels and appetite. This review outlines the physiological role of amylin and highlights recent clinical studies exploring its therapeutic potential in diabetes and obesity. Amylin lowers postprandial glucose levels by delaying ...

Rejili M, Hussain MS, Khan Y, Haouala F, Ganesan S, Sahoo S et al.

Obesity is a chronic, relapsing metabolic disorder driven by complex genetic and environmental factors, leading to an imbalance in energy regulation. Despite the presence of GLP-1 receptor agonists with induced mild weight loss, there are significant unmet clinical needs with poor efficacy and to...

Muskiet MHA, Nardone M, Rensen PCN, Cherney DZI, Cooper ME

We hypothesise that amylin receptor agonists (eg, pramlintide) and dual amylin and calcitonin-receptor agonists (eg, cagrilintide), which are emerging treatments for obesity and type 2 diabetes, can activate the renin-angiotensin system (RAS) and potentially undermine the cardiorenal benefits of ...

Odabassian M, Tsoukas MA, Cohen E, Pasqua MR, Rutkowski J, Haidar A et al.

Type 1 diabetes is treated with exogenous insulin using multiple daily injections or insulin pumps. However, both strategies require carbohydrate counting for prandial insulin dosing, which is both burdensome and error prone.We conducted a pilot, randomized, controlled study to eliminate carbohyd...

Wu J, Yin T, Zhang Z, Yin R, Metwally E, Li K et al.

Diabetic kidney disease (DKD) is a major microvascular complication of diabetes. Current diagnostic markers (e.g., UACR, eGFR) exhibit limitations in sensitivity and specificity, underscoring the need for novel approaches.We integrated single-cell RNA sequencing (scRNA-seq) of kidney tissues from...

Kern KA, DiBrog AM, Demieri E, Przybysz JT, Clark SD, Mietlicki-Baase EG et al.

Amylin is a feeding-suppressive hormone which acts centrally in the control of energy balance. Some evidence suggests it reduces motivation for food rewards. Pramlintide is a synthetic amylin analog that is used clinically in the treatment of diabetes, and it also reduces feeding and weight gain....

Stewart R, Ezell KM, Bell DS, Corner B, McMinn A, Cogan JD et al.

Nizon-Isidor syndrome is a rare disorder caused by heterozygous variants in MED12L, with only eight documented cases in the literature. Here, we present three additional cases of this syndrome. Proband 1 was a 7-year-old female who presented with developmental delay, right-leg hemihypertrophy, la...

Saeed ZI, Ambalavanan J, Rayan MN, Patadia P, Shah VN

With the increasing prevalence of double diabetes (features of type 2 diabetes in people with type 1 diabetes (T1D)), there is a growing interest in using noninsulin therapies to improve glycemic outcomes, promote weight loss, and reduce cardiovascular risk in T1D. In this narrative review, we su...

Pons Torres B, Sala-Mira I, Furió-Novejarque C, Sanz R, García P, Díez JL et al.

Pramlintide's capability to delay gastric emptying has motivated its use in artificial pancreas systems, accompanying insulin as a control action. Due to the scarcity of pramlintide simulation models in the literature, in silico testing of insulin-plus-pramlintide strategies is not widely used. T...

Moreno-Ajona D, Gosalia H, Hoffmann J, Goadsby PJ

Here, we review the available evidence implicating amylin in migraine, its relationship with calcitonin gene-related peptide (CGRP) and its potential utility as a therapeutic target. The pathophysiology of migraine is currently better understood and the role of CGRP is key. Treatments targeting t...

Walker CS, Aitken JF, Vazhoor Amarsingh G, Zhang S, Cooper GJS

The identification of amylin as a glucoregulatory peptide hormone with roles in meal-ending satiation sparked a surge of experimental development, which culminated in the amylin mimetic drug pramlintide. Pramlintide was approved by the FDA in 2005 for the treatment of type 1 diabetes mellitus and...

Volčanšek Š, Koceva A, Jensterle M, Janež A, Muzurović E

Precision diabetology is increasingly becoming diabetes phenotype-driven, whereby the specific hormonal imbalances involved are taken into consideration. Concomitantly, body weight-favorable therapeutic approaches are being dictated by the obesity pandemic, which extends to all diabetes subpopula...

Almeida MS, Sanches MP, Tonet NS, Zuglianello C, Morari J, Velloso LA et al.

Pramlintide is an amylin analog developed as a complementary treatment for diabetes. However, it requires several subcutaneous injections, reducing patients' adherence. Since the intranasal route might be an alternative for drug administration, we evaluated whether intranasal pramlintide treatmen...

Byun S, Maric I, Börchers S, Sotzen MR, Olekanma D, Hayes MR et al.

Amylin, a pancreatic peptide, has a well-established role in feeding behavior control. Amylin analogues are clinically utilized in patients with diabetes and are under investigation as potential anti-obesity pharmacotherapies. The neural circuits underlying actions of amylin on behavior are not w...

Vatsia SK, Levidy MF, Rowe ND, Meister AS, Bible JE

Retrospective analysis.To evaluate the effects of GLP-1 agonist therapy upon the incidence of pseudarthrosis in patients undergoing multilevel cervical spinal fusion.The rising prevalence of obesity and diabetes mellitus has rendered the usage of glucagon-like peptide-1 receptor (GLP-1) agonists ...

Apostolopoulou M, Lambadiari V, Roden M, Dimitriadis GD

People with type 1 diabetes (T1D) are usually considered to exclusively exhibit β-cell failure, but they frequently also feature insulin resistance. This review discusses the mechanisms, clinical features, and therapeutic relevance of insulin resistance by focusing mainly on human studies u...